Zenas BioPharma, Inc.
ZBIO
$34.50
-$2.57-6.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -70.00% | -70.00% | -90.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -70.00% | -70.00% | -90.00% | -100.00% |
| Cost of Revenue | 46.29% | 86.30% | 124.87% | 131.77% | 98.60% |
| Gross Profit | -32.70% | -302.05% | -687.08% | -1,236.98% | -1,875.66% |
| SG&A Expenses | 117.26% | 115.06% | 103.35% | 73.82% | 41.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.37% | 91.76% | 120.27% | 118.92% | 86.45% |
| Operating Income | -47.09% | -235.08% | -387.22% | -503.70% | -522.95% |
| Income Before Tax | -47.40% | -224.60% | -257.02% | -325.16% | -308.07% |
| Income Tax Expenses | -18.94% | -18.94% | -25.58% | 42.52% | -- |
| Earnings from Continuing Operations | -47.24% | -223.26% | -255.16% | -322.87% | -309.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.24% | -223.26% | -255.16% | -322.87% | -309.03% |
| EBIT | -47.09% | -235.08% | -387.22% | -503.70% | -522.95% |
| EBITDA | -47.18% | -235.63% | -388.48% | -505.72% | -525.48% |
| EPS Basic | 92.82% | 85.05% | -5.88% | -99.08% | -200.33% |
| Normalized Basic EPS | 92.98% | 75.92% | -37.76% | -177.09% | -330.95% |
| EPS Diluted | 92.82% | 85.17% | -4.24% | -95.35% | -193.85% |
| Normalized Diluted EPS | 92.98% | 78.64% | -15.43% | -121.35% | -230.94% |
| Average Basic Shares Outstanding | 1,257.20% | 2,049.66% | 1,408.09% | 761.28% | 103.14% |
| Average Diluted Shares Outstanding | 1,257.20% | 1,931.55% | 1,324.80% | 713.41% | 91.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |